TBI Clinical Study IRB Approval, Stem Cell Therapeutics Corp, (TSX V: SSS)
SCT or TSX VENTURE: SSS’s IRB (Institutional Review Board) at the University of Calgary/Foothills Hospital has approved the SCT-sponsored investigator lead Phase IIa study entitled “A Phase IIa, Single Center, Open Label Study to Characterize the Safety of Human Chorionic Gonadotrophin (hCG) and Epoeitin Alpha (EPO) in Traumatic Brain Injury“.
The study lead by Dr David Zygun, of the University of Calgary is a single center open label study to characterize the safety of hCG and EPO in traumatic brain injury patients.
- A series of efficacy endpoints are part of the trial design in order to access various aspects of neurological status;
- Management continues to focus its efforts on pursuing the end-of-Phase II meeting with the FDA for the NTx®-265 stroke therapy while concurrently reviewing alternatives for pursuing the traumatic brain injury (“TBI”) and multiple sclerosis (“MS”) study opportunities.
Categories: Stem Cell Technology
